Fifty‐two percent were ≤ 60 years old; 62% were men; 74% were Caucasian; 34% had melanoma; 25% had high TMB; and 68% received a PD1/PDL1 inhibitor as a single agent (Table 2). Here, CD274 is linked to melanoma.